Pharmacological characterization To examine whether the potent weight loss observed in vivo after GLP-1MK-801 treatment is attributable to pharmacological synergy between GLP-1 and MK-801 or consequential to altered pharmacokinetic properties of the parent GLP-1 analogue, we designed and synthesized a conjugate comprising an inactive MK-801 surrogate 22 (Supplementary Fig
You can learn more about how we ensure our content is accurate and current by reading our editorial policy.
(3) synaptic morphology
Ferroptosis-associated therapeutic opportunities Ferroptosis is linked to the occurrence and progression of a number of heart illnesses, including myocardial I/R injury, AF, hypertensive heart disease, diabetic heart disease
Grillo, A., Salvi, L., Coruzzi, P., Salvi, P., Parati, G